Enhanced Specific Activity by Multichelation of Exendin-3 Leads To

Dec 11, 2017 - (21) When using optimal labeling conditions, like metal-free materials, appropriate temperatures, or buffers, still leaves room for imp...
0 downloads 13 Views 1MB Size
Subscriber access provided by UNIV OF DURHAM

Article

Enhanced specific activity by multi-chelation of exendin-3 leads to improved image quality and in vivo beta cell imaging Lieke Joosten, Maarten Brom, Hanneke Peeters, Sandra Heskamp, Martin Behe, Otto C. Boerman, and Martin Gotthardt Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.7b00853 • Publication Date (Web): 11 Dec 2017 Downloaded from http://pubs.acs.org on December 20, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 27 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

1

Enhanced specific activity by multi-chelation of exendin-3 leads to improved image quality and in

2

vivo beta cell imaging

3 1

1

4

Lieke Joosten *, Maarten Brom , Hanneke Peeters

5

Martin Gotthardt

1, 3

1

2

1

, Sandra Heskamp , Martin Béhé , Otto Boerman ,

1

6 7

1

8

6500 HB Nijmegen, The Netherlands

9

2

Department of Radiology and Nuclear Medicine, Radboud university medical center, PO Box 9101

Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, 5232 Villigen,

10

Switzerland

11

Present address:

12

3

13

Biology, Maastricht University Medical Center, Maastricht, The Netherlands

Maastricht Radiation Oncology (Maastro) Lab, GROW – School for Oncology and Developmental

14 15 16 17 18 19 20 21

(*)

Lieke Joosten

22

Department of Radiology and Nuclear Medicine, Radboud university medical Center, PO Box

23

9101, 6500 HB Nijmegen, The Netherlands

24

Telephone/fax: +31 24 36 67319 / +31 24 36 18942

25

Email: [email protected]

ACS Paragon Plus Environment

Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

26

Table of Contents/Abstract graphic

27

28

2 ACS Paragon Plus Environment

Page 2 of 27

Page 3 of 27 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

29

Molecular Pharmaceutics

Abstract

30 31

Objective: Glucagon like peptide-1 receptor (GLP-1R) targeting using radiolabeled exendin is a promising

32

approach to non-invasively visualize and determine beta cell mass (BCM), which could help to unravel the

33

pathophysiology of diabetes. However, saturation of the GLP-1R on beta cells occurs at low peptide

34

doses, since the number of receptors expressed under physiological conditions is low. Therefore, tracers

35

with high specific activities are required to sensitively image small variations in BCM. Here, we describe a

36

novel exendin-3-based radiotracer with multiple chelators and determined its potential for in vivo beta cell

37

imaging.

38

Methods: Exendin-3 was modified by adding six lysine residues C-terminally conjugated with one, two or

39

six DTPA moieties. All compounds were labeled with

40

vitro using GLP-1R expressing cells. The in vivo behavior of the

41

BALB/c nude mice with a subcutaneous GLP-1R expressing tumor (INS-1). Brown Norway rats were used

42

for SPECT visualization of the pancreatic BCM.

43

Results: Addition of six lysine and six DTPA residues (hexendin(40-45)) resulted in a seven-fold increase

44

in specific activity (from 0.73 GBq/nmol to 5.54 GBq/nmol). IC50 values varied between 5.2 and 69.5 nM.

45

All compounds with two or six lysine and DTPA residues had a significantly lower receptor affinity than

46

[Lys (DTPA)]exendin-3 (4.4 nM, p < 0.05). The biodistribution in mice revealed no significant decrease in

47

pancreatic uptake after addition of six lysine and DTPA molecules. Hexendin(40-45) showed a six-fold

48

increase

49

[Lys (DTPA)]exendin-3 (182.7 ± 42.3 kBq vs. 28.8 ± 6.0 kBq, p